Asian Spectator

Men's Weekly

.

Positive Phase III Clinical Results for EirGenix's Proposed Tr...

  • Written by LATEST ASIANET NEWS RELEASES
  • Published in Asia Net
TAIPEI, March 23, 2021 /PRNewswire-AsiaNet/ -- In a press conference today, EirGenix, Inc. (6589.TT) announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimilar, EG12014 (proposed trastuzumab biosimilar, also called EGI014), has met its primary ...

Authors: LATEST ASIANET NEWS RELEASES

Read more

Magazine

Kenapa nilai zakat Indonesia masih rendah meski pembayaran zakat digital sudah di mana-mana?

● Potensi zakat nasional tembus ratusan triliun.● Dana sebesar itu bisa jadi dana segar pembangunan dan pengentasan kemiskinan nasional.● Pembayaran online ternyata tak mendongkrak p...

‘Lebaran blues’ dan rasa kehilangan: Bagaimana momen hari raya bisa memicu duka

Tampak belakang seorang perempuan mengenakan pakaian salat duduk di kursi roda pada perayaan Idulfitri.Creativa Images/Shutterstock● Bagi mereka yang sedang berduka, hari raya dapat membuat rasa...

The silver lining in Europe’s deforestation law delay: A chance to build fairer supply chains

When you reach for a “palm-oil-free” label at the supermarket, you likely feel you’re doing your part to save orangutans and protect biodiversity. However, the reality behind that la...